Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders

Ophthalmology

Volumn 110, Issue 5, 2003, Pages 1061-1065

  Baltatzis, Stefanos ^a   Tufail, Fehma ^a   Yu, Ellen N ^a   Vredeveld, Cindy M ^a   Foster, C Stephen ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DAPSONE; ETANERCEPT; IMMUNOMODULATING AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ADULT; ALLERGIC REACTION; ALLERGY; ANOREXIA; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EYE INFLAMMATION; FATIGUE; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAUSEA; PRIORITY JOURNAL; STEROID THERAPY; THORAX PAIN; THRUSH; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY;

EID: 0037542699     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00092-7     Document Type: Article

References (12)

1. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001;72:13-21.
2. Budde K, Glander P, Bauer S, et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000; 38:1213-6.
3. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001;72:245-50.
4. Spatz S, Rudnicka A, McDonald CJ. Mycophenolic acid in psoriasis. Br J Dermatol 1978;98:429-35.
5. Boumpas DT, Kritikos HD, Daskalakis NG. Perspective on future therapy of vasculitis. Curr Rheumatol Rep 2000;2:423-9.
6. Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001;10:203-8.
7. Meihsler W, Reinisch W, Moser G, et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 2001;96:782-7.
8. Schwarz A. New aspects of the treatment of nephrotic syndrome. J Am Soc Nephrol 2001;12(Suppl 17):S44-7.
9. Chanaud NP III, Vistica BP, Eugin E, et al. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res 1995;61:429-34.
10. Zurdel J, Aboalchamat B, Zierhut M, et al. [Early clinical results with mycophenolate mofetil in immunosuppressive therapy of ocular pemphigoid.]. Klin Monatsbl Augenheilkd 2001;218:222-8.
11. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999;106:370-4.
12. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234-5.